Published on 01 January 2022

Available IPD datapackage for study 'Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety And Efficacy Of 2 Doses Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate With Inadequate Response To TNF Inhibitors'

Pfizer Inc.

Description

This study will test if CP-690,550 is safe and effective in rheumatoid arthritis patients taking methotrexate who have an inadequate response to tumor necrosis factor inhibitor treatment.

Citations (0)

No citations found

It looks like this dataset has no citations.

Mentions (0)

No mentions found

It looks like this dataset has not been mentioned in any sources.

Metrics

Dataset Index

0.8

FAIR Score

31%

Citations

Mentions

Metrics Over Time

Publication Details

DOI

10.25934/pr00005059.0

Publisher

Vivli

Assigned Domain

Subfield

Rheumatology

Field

Medicine

Domain

Health Sciences

Confidence Score

65%

Source

Scholar Data Model

Keywords

Conditions: Arthritis, RheumatoidInterventions: CP-690,550Interventions: Placebo

Normalization Factors

13.46

CTw

1.00

MTw

1.00